These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10051763)

  • 21. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia.
    Pick CG; Peter Y; Schreiber S; Weizman R
    Brain Res; 1997 Jan; 744(1):41-6. PubMed ID: 9030411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
    Crain SM; Shen KF
    Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression.
    Shook JE; Watkins WD; Camporesi EM
    Am Rev Respir Dis; 1990 Oct; 142(4):895-909. PubMed ID: 2171388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-analgesic effects of opioids: opioid-induced respiratory depression.
    Boom M; Niesters M; Sarton E; Aarts L; Smith TW; Dahan A
    Curr Pharm Des; 2012; 18(37):5994-6004. PubMed ID: 22747535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid agonist-antagonist drugs in acute and chronic pain states.
    Hoskin PJ; Hanks GW
    Drugs; 1991 Mar; 41(3):326-44. PubMed ID: 1711441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine.
    Sarton E; Teppema L; Dahan A
    Adv Exp Med Biol; 2008; 605():486-91. PubMed ID: 18085322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression.
    Lötsch J; Skarke C; Schneider A; Hummel T; Geisslinger G
    Clin Pharmacol Ther; 2005 Sep; 78(3):278-87. PubMed ID: 16153398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system.
    Braida D; Pozzi M; Cavallini R; Sala M
    Neuroscience; 2001; 104(4):923-6. PubMed ID: 11457579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis.
    Janas A; Folwarczna J
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):175-185. PubMed ID: 27896372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory and locomotor stimulation by low doses of dermorphin, a mu1 receptor-mediated effect.
    Paakkari P; Paakkari I; Sirén AL; Feuerstein G
    J Pharmacol Exp Ther; 1990 Jan; 252(1):235-40. PubMed ID: 1967644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration.
    Canestrelli C; Marie N; Noble F
    Int J Neuropsychopharmacol; 2014 Sep; 17(9):1367-73. PubMed ID: 24606726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parental history of chronic pain may be associated with impairments in endogenous opioid analgesic systems.
    Bruehl S; Chung OY
    Pain; 2006 Oct; 124(3):287-294. PubMed ID: 16725261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of endogenous opioid system in scorpion toxin-induced antinociception in mice.
    Martin-Eauclaire MF; Abbas N; Sauze N; Mercier L; Berge-Lefranc JL; Condo J; Bougis PE; Guieu R
    Neurosci Lett; 2010 Sep; 482(1):45-50. PubMed ID: 20619318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous opioids and hypoxic survival.
    Howman SF; Groeger JS
    Crit Care Med; 1999 Sep; 27(9):2057-8. PubMed ID: 10507657
    [No Abstract]   [Full Text] [Related]  

  • 38. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label nondeceptive placebo analgesia is blocked by the opioid antagonist naloxone.
    Benedetti F; Shaibani A; Arduino C; Thoen W
    Pain; 2023 May; 164(5):984-990. PubMed ID: 36165878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal.
    Lewanowitsch T; Irvine RJ
    Eur J Pharmacol; 2002 Jun; 445(1-2):61-7. PubMed ID: 12065195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.